Owlstone Medical Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Owlstone Medical Ltd.
The oversubscribed $58m funding round will enable the company to further work on its first-in-class breath biopsy technology, which aims to provide a cheap and convenient screening tool for several diseases.
Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.
Thermo Fisher Scientific has signed a collaboration with Cambridge, UK-based Owlstone Medical to identify novel biomarkers.
Owlstone Medical has signed another major collaboration agreement with a big pharma company to use its breath biopsy services. The Cambridge, UK company is partnering with AstraZeneca to to identify novel breath biomarkers for asthma and COPD.
- Research, Analytical Equipment & Supplies
- Diagnostic Equipment & Supplies
In Vitro Diagnostics
- Chemistry, Immunoassay
- Other Names / Subsidiaries
- Owlstone Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.